

In silico Discovery of STRA 6 Vitamin A Receptor, as a Novel Binding Receptor of COVID-19

Mahmoud Elkazzaz¹, Amr Ahmed², Yousry Esam-Eldin Abo-Amer³, Tamer Haydara⁴, Wafa Ali ELtayb⁵, Mohammad Shahbaz Khan⁶, Kunal Bhattacharya⁷, Salma Alkhamash⁸, Hadeer Mattar⁹, Saba beigh¹⁰, Mohammed F. Abo El Magd¹¹, Abdullah Haikal¹², Islem Abid¹³, Amr S. Abouzied^{14,15}, Israa M. Shamkh^{16,*}

¹Department of Chemistry and Biochemistry, Faculty of Science, Damietta University, Damietta, EGYPT.

²Department Public Health, Director of Tuberculosis Ghubera Mobile Team, First Health Cluster, Ministry of Health, Riyadh, SAUDI ARABIA.

³Department of Internal Medicine, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, EGYPT.

⁴Department Hepatology, Gastroenterology, and Infectious Diseases, Mahala Hepatology Teaching Hospital, EGYPT.

⁵Department Biotechnology, Faculty of Science and Technology, Shendi University, Shendi, Nher Anile, SUDAN.

⁶Children's National Hospital, Washington, DC, USA.

⁷Pratiksha Institute of Pharmaceutical Sciences, Guwahati, Assam, INDIA.

⁸Department of Immunology and Allergy, Consultant Immunology and Allergy, King Abdullah Medical City-Makkah, SAUDI ARABIA.

⁹School of Applied Biomedical Sciences, Al-Baha University, Al-Baha, SAUDI ARABIA.

¹⁰Department of Public Health, Faculty of Applied Medical Sciences, Albaha University, Albaha, SAUDI ARABIA.

¹¹Zoology and Nematode Department, Faculty of Agriculture, Al Azhar University, Cairo, EGYPT.

¹²Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, EGYPT.

¹³Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, SAUDI ARABIA.

¹⁴Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, SAUDI ARABIA.

¹⁵Department of Pharmaceutical Chemistry, National Organization for Drug Control and Research (NODCAR), Giza, EGYPT.

¹⁶Chemo and Bioinformatics Lab, Bio Search Research Institution, BSRI, Giza, EGYPT.

ABSTRACT

A global pandemic of pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, at the end of 2019. Although, the ACE2 receptor has been demonstrated to be the main entry receptor of COVID-19, but our docking analysis, predicted and discovered a novel receptor termed STRA 6 that may play a critical role in the pathogenicity of COVID-19. STRA6 receptor expressed in many organs and immune cells, upregulated by retinoic acid jm6 (STRA 6) was the first protein to be identified in a novel category of proteins, cytokine signaling transporters, due to its ability to function as both a cell surface receptor and a membrane protein that binds to retinol binding protein facilitating cellular uptake of retinol. The primary ligand of STRA6 (vitamin/retinol) was shown to be drastically reduced during COVID-19 infection, which agrees with our findings. We analyze the STRA6 and ACE2 receptor networks to predict the specific association among certain other proteins which might rely on similar functionality. Molecular docking showed a high affinity between the Spike protein with STRA6, the docking score of COVID-19 spike protein with STRA6 (-354.68) kcal/mol was higher than the docking score of spike protein with ACE2 (-341.21) kcal/mol. Results of MD simulations revealed significant stability of the spike protein with STRA6 up to 100 ns. SARS-CoV-2 spike protein binds strongly and directly to STRA6. Which are highly expressed in Lymphatic system and Immune cells. This study paves the way towards understanding the complex mechanism of existing of covid-19 infection complications such as immune suppression and ineffective RIG-I pathway. Restoring the balance between the STRA6 and ACE2 in the context of spike protein RBD may be promising target in SARS CoV-2 Pathogenesis and may reveal new drug targets for new variants of COVID-19.

Keywords: COVID-19, STRA6, ACE2, Molecular docking.

Correspondence:

Dr. Israa M. Shamkh

Chemo and Bioinformatics Lab, Bio Search Research Institution, BSRI, Giza 12613, EGYPT.

Email: israamshamkh@gmail.com

Received: 23-03-2023;

Revised: 24-03-2023;

Accepted: 14-08-2023.

INTRODUCTION

Normal cellular function depends on Vitamin A homeostasis. Plasma Retinol-Binding Protein (RBP) is the only specialized transporter of retinol, the most common form of Vitamin A, in the plasma. By recognizing RBP-retinol and triggering retinol release and internalization, the integral membrane receptor STRA6 initiates and controls cellular uptake of Vitamin A.¹ Due to its capacity to function as both a membrane protein and a cell surface



DOI: 10.5530/ijper.57.4.126

Copyright Information :

Copyright Author (s) 2023 Distributed under Creative Commons CC-BY 4.0

Publishing Partner : EManuscript Tech. [www.emanuscript.in]

receptor, which allows it to attach to retinol binding protein, STRA6 is a particularly significant receptor. It was discovered to be the first protein to be recognized as a cytokine signaling transporter.^{2,3} Because of the critical function of Vitamin A in the immune cell development, STRA6 was found to be expressed on all subsets of peripheral blood mononuclear cells at varying amounts. A recent study showed that all T cell, monocyte, natural killer cell and dendritic cell subsets expressed the retinol binding receptor (STRA6).³ STRA6 initiates cellular retinol uptake, in immune cells for improving the immune system homeostasis in various populations.³ The association of intracellular proteins with Vitamin A absorption mediated by STRA6 from holo-retinol/retinol binding protein complex (holo-RBP) has been demonstrated by several independent investigations^{4,5} and the mechanism by which it joins to specific intracellular proteins has been explained.⁶ It was recently showed that Single Nucleotide Polymorphisms or mutations (SNPs) in STRA6 are connected with the recurrence of type 2 diabetes in humans.⁷ Moreover, Pasutto *et al.*⁷ reported that STRA 6 mutations associated with lung malformations and many heart, eye diaphragm as well as retardation in mentality as in syndrome of Matthew-Wood in humans, validating its reported functions in Vitamin A uptake by cells as Vitamin A/retinoic acid is very critical in the process of organogenesis. STRA 6 mutations results in a broad spectrum of complication related to malformations counting congenital heart defects, lung hypoplasia, anophthalmia, alveolar capillary dysplasia, diaphragmatic hernia, and mental retardation.⁸

Recent findings showed that mutations in the gene of STRA 6 are connected to the congenital microphthalmia of eye malformations, coloboma and anophthalmia.^{7,9,10} STRA 6 genetic null mutation in mice model leads to significant reduction of retinoid in the neurosensory retina and retinal pigment epithelium, diminished eye morphology and visual responses, despite the fact the last-mentioned complication is not as serious as in individuals with mutant STRA6.¹¹ According to a recent publication, STRA 6 is not only a receptor of Vitamin A transporter, but it can also act as a cytokine receptor. Upon attaching to holo-RBP, STRA 6 is directly phosphorylated at its region of tyrosine residue 643, which, in turn, triggers and recruits activation of STAT 5 and the Janus Kinase 2 gene, (JAK2).¹²

STRA 6 seems to be very important receptor and transporter of Vitamin A which critically participate in synthesis of retinoic acid which is the active and the main Vitamin A metabolite. All animals need a nutrient that contains Vitamin A. It is required for the proper process of vision in its form of retinaldehyde (retinal);¹³ as Retinoic Acids (RAs), it provides ligands for RAR (retinoic acid receptor) and RXR (retinoid X receptor) nuclear receptor transcription factors.¹⁴ Consequently, retinoid metabolism affects numerous biological processes¹⁵ with many disease implications from viral infection and cancer to blindness.^{16,17} In the world Vitamin A deficiency is the third most popular nutritional

deficiency, affecting of millions of children and pregnant women life.¹⁸

Retinoic Acid (RA) is a morphogen and important metabolite synthesized from Vitamin A (retinol).¹⁹ Two dehydrogenase-catalyzed enzymatic reactions are essential for the production of RA from retinol. Vitamin A (Retinol) is converted to retinal, which is then converted to RA. The RA interacts with Retinoic acid X Receptor (RXR) and Retinoic Acid Receptor (RAR) which then regulates the expression of targeted gene.¹⁹ Based on the investigations and previous researches it is clear that RA play a major modulatory function in the immune system. Actually, retinol is an important hormone and immune system regulator. It participates with zinc for improving the function of the immune system.²⁰ Retinoids are molecules that possess qualitative activity relative to all-trans retinol (Vitamin A), that includes all-trans-Retinoic Acid (RA) retinyl-esters and all-trans retinal.²⁰ RA is the biologically active retinoid metabolite that, works through its receptors RA receptors (RAR β , α and γ) regulates the generation of various genes involved many biological pathways including both innate and adaptive immune responses.²¹ Retinoids act as enhancers of the T-cell mediated innate immune responses and adaptive immunity via induction of antigen presenting Dendritic Cells (DCs), NK cells and Innate Lymphoid Cells (ILCs).^{21,22}

It has been established that retinoic acid induces gut-homing receptors on B cells, T cells and ILCs. A mounting body of evidence indicates that RA exerts far-reaching impact on fate and functional differentiation of these lymphocytes.²³ Retinoids can directly stimulate the messenger RNA (mRNA) expression of Interferon-Stimulated Gene (ISG), including IFN Regulatory Factor 1 (IRF-1) and Retinoic acid-Inducible Gene I (RIG-I).²⁴⁻²⁶ Furthermore, retinoic acid plays critical physiological roles in synaptic plasticity, learning and memory,²⁷ hormone production^{27,28} and adult neurogenesis.²⁷ Retinoic acid insufficiency in the olfactory epithelium, both in mouse and chick models, causes progenitor cell maintenance failure and, consequently, olfactory neurons differentiation is not maintained. An explant system showed that renewal of olfactory neurons is inhibited if retinoic acid synthesis was failed in the olfactory epithelium.²⁹ In the immune system, Retinoic Acid (RA), metabolite of Vitamin A is known for its critical function in increasing gut-homing molecules in B and T lymphocyte cells, boosting tolerance and regulatory T cells (Tregs).^{30,31} Synthetic and natural retinoids also have potent inhibitory effects on replication of many viruses, such as MeV, cytomegalovirus, influenza, norovirus and Hepatitis B Virus (HBV).^{27-30,32,33} There is additional evidence that retinoid signaling activation can effectively suppress coronaviruses.³⁴

Our docking study reveals that COVID-19 spike protein binds directly to the integral membrane receptor (STRA 6). STRA 6 mediates cellular uptake of retinol (Vitamin A) by recognizing a molecule of RBP-retinol to trigger release and internalization

of retino. Therefore COVID-19 may lead to down regulation of STRA 6 receptor leading to inhibition the regulatory function of retinoic acid and helps in existing of pre- and post-covid-19 infection symptoms and complications such as immune suppression, ineffective RIG-I pathway and interferon inhibition.

MATERIALS AND METHODS

Sequence Retrieval

The amino acid sequence of SARS CoV-2 spike protein with STRA6 and ACE2 PDB (7DMU, 5SY1) for the Spike-ACE2 and STRA6 receptor was retrieved from the protein data bank in FASTA format as per earlier researchers,^{35,36} to determine the 3-D structure of the target protein for further conformational investigations.

Molecular docking

HDOCK server (<http://hdock.phys.hust.edu.cn/>) was used to perform molecular docking to assess the binding mode of SARS CoV-2 spike protein with STRA6 and ACE2 (Angiotensin-converting enzyme 2). PDB accession numbers (7DMU, 5SY1) for the Spike-ACE2 and STRA6 receptor proteins illustrate their binding mechanism. To evaluate whether the spike protein of the virus binds with the STRA6 receptor or not and, if so, with what affinity the binding happens, we studied the Spike-ACE 2 and STRA6 receptor proteins. The HDOCK server was used to conduct docking studies on the Spike-ACE 2 and STRA6 receptor proteins.

The spike protein was put into the SAMSON software (<https://www.samson-connect.net>) and Discovery Studio Visualizer (<https://discover.3ds.com/discovery-studio-visualizer-download>) after downloading it from the PDB with accession number 6MOJ. Then, we separated the ACE 2 and Spike proteins to conduct docking between them. Finally, we used the result as a control result to test and know how complex the spike-STRA6 receptor is and how much its efficiency, after that, the HDOCK server performed global docking to sample putative binding modes using an FFT-based search method. Following that, the putative binding modes were evaluated.

Protein-Protein Interaction Network Analysis

The STRA6 receptor protein was submitted to STRING v10.0 (<https://string-db.org/>) to analyze functional STRA6-associated networks, where interactions were analyzed at a medium confidence level as per the investigation of earlier researchers.³⁷⁻³⁹

$$RMSD_x = \sqrt{\frac{1}{N} \sum_{i=1}^N (r_i'(t_x) - r_i(t_{ref}))^2}$$

Molecular Dynamics Simulation

The outcomes of simulations of molecular dynamics are immensely complex.⁴⁰ The Cartesian values of each atom in the system are recorded together with each time interval of the trajectory, which can again fluctuate in length from hundreds to millions of steps. The RMSD (root-mean-square deviation) is a commonly used parameter for topological isolation across variables. It establishes the usual separation between a collection of atoms such as the backbone atoms of a protein.⁴¹ The number serves as a gauge of how much the protein shape has altered when the RMSD is calculated over two different sets of atomic coordinates, such as two points in the trajectory.

The RMSF (root-mean-square fluctuation) determines the quantum state mean distances throughout time (for instance, from a peptide sequence) from a point of comparison (typically the time-averaged position of the particle). Therefore, RMSF investigates the structural components that deviate most from their mean composition.⁴²

The trajectory files were analyzed using the `g_rms` and `g_rmsf` GROMACS utilities to obtain the RMSD and Root Mean Square Fluctuation (RMSF) values. The numbers of distinct intermolecular hydrogen bonds formed during the simulation were calculated using the `g_hbond` utility. The trajectory files of the Principal Component Analysis (PCA) were analyzed using the `g_covar` and `g_anaeig` utilities in GROMACS, in this order. The analysis of the secondary structure elements of the protein was performed using the `do_dssp` command, which utilizes the DSSP program.⁴³

RESULTS AND DISCUSSION

We use computational approaches to investigate the mechanistic process for investigating the role of the retinal receptor-STRA6 as a novel binding receptor in SARS CoV-2. We plan to anticipate the receptor usage infectivity of potential SARS-CoV to identify their anticipated genetic or historical origins based on the patterns of their spike proteins and the known particle structural features of the initial SARS-CoV RBD/ACE2 complexes. Here, we regularly employ this forecasting approach based on the recently released data of the 2019-nCoV RBD to offer hitherto unheard-of insights into the receptor utilisation and expected invading potential of 2019-nCoV.

Furthermore, we study the receptor binding and protease activations of SARS-CoV-2 spike using SARS-CoV spike as a baseline. Our results, which are based on computational analysis, highlight significant SARS-CoV-2 cell entry routes, where the virus's spike protein selectively attaches to with an integral receptor complex, likely facilitating signal transduction, cell transmissibility, and widespread transmission (STRA 6). The intention was to learn more about the molecular mechanism

$$RMSF_i = \sqrt{\frac{1}{T} \sum_{t=1}^T \langle (r'_i(t)) - r_i(t_{ref}) \rangle^2}$$

as per earlier researchers,^{44,45} through which the SARS-CoV-2 virus causes patients to have difficult symptoms by examining the binding affinity and mode of interaction between the two proteins. This might pave the way for therapeutic strategies that do not only rely on ACE2 to make first contact with the spike protein of the virus. By creating and docking the spike protein, ACE2 protein, and STRA6 receptor using the HDOCK server, the mode and process of the interaction were examined in this study, and our analysis was compared to past studies.⁴⁶⁻⁴⁹

We reinvestigate whether STRA6, particularly recognises RBP-retinol and encourages its escape and enculturation, improves Retinol (Vitamin A) absorption into cells. The findings contradict prior claims about SARS-CoV-2 that retinol and retinoids are efficient therapies for COVID-19 sickness and associated etiologically ambiguous symptoms. Because of our deterministic explorations, which are very remarkable methods where Novel Binding Receptor in SARS CoV-2 provides ground-breaking feedback to regulate RBD/ACE2 complexes in the context of Spike proteins to boost attempt to escape immunologic regulatory, the current study offers a novel insight of potential therapeutic strategies by targeting SARS-CoV-2 specific sites.

Protein-protein docking (STRA6 and SARS CoV-2 spike protein)

By using molecular docking, the molecules in a libraries are compared based on their potential for the selected receptors as per the role of Dias, de Azevedo.⁴⁴ The folding of the biomolecules into the cavities of the receptor is necessary for the binding energy, which depends on a number of interactions, including

charge transfer, hydrogen bonds, Van der Waals interactions, and others. We observed that Hydrogen bonding can be ordinary or non-conventional, therefore the production of regular hydrogen bonds (H-bonds) between molecules with adequate functional groups that may serve as H-bond acceptors is dependable as per earlier research.⁴⁹ The static phase of the receptor serves as the foundation for molecular docking screening, thus it's critical to understand the MD trajectories across this interaction between receptor and ligands as well as the change in energy throughout dynamics.

The interactive residues of the target protein STRA6 and the ligand spike protein can aid the design and development of more efficient and specific drugs for their target protein. The docking of STRA6 target protein with the viral spike protein revealed the involvement of the spike protein in the extracellular and membrane part of the STRA6 receptor. It showed the amino acid residues of STRA6 interacting with those of the spike protein, which are responsible for the protein-protein complex formation. The STRA6-spike protein complex (PDB ID 5SY1 and 6LZG, respectively) reveals that chains A and B have Align_lengths of 582 and 194, and then the quarry coverage of 0.793 and 1.000 and sequence identity of 96.2% and 100.0%, respectively. The surface view of the complex indicates that the binding pocket of the STRA6-spike and spike-ACE2 protein complexes have RMSD values of 189.44 Å and 1.00 Å, respectively.

The docking scores are -341.21, and -354.68 kcal/mol, and the quality of the ACE receptor and the ligand represented by the LGscore and MaxSub scores are 2.416, 0.147, respectively, confirming the correctness of the structures. On the other hand, the STRA6 receptor protein's LGscore and MaxSub scores are 5.056, and 0.217, showing that the structures are very good and correct for the spike ligand and the receptor protein, as seen in Table 1. The RDB binding motif outside the cell, the STRA6 receptor's membrane component outside the cell, and the

Table 1: Complex Template Information and Docking scores (spike protein-human STRA6 receptor protein) and (spike protein-ACE 2).

Complex Template Information between (STRA6 –SARS CoV-2 Spike protein)									
Molecule	PDB ID	Chain ID	Align length	Coverage	Seq ID (%)	Docking Score	Ligand rmsd (Å)	LGscore	MaxSub:
Receptor (STRA6)	5SY1	A	582	0.793	96.2	-354.68	229.41	2.416	0.147
Ligand (spike)	6LZG	B	194	1.000	100.0			5.056	0.217
Complex Template Information between (ACE2 – SARS CoV-2 Spike protein)									
Molecule	PDB ID	Chain ID	Align length	Coverage	Seq ID (%)	Docking Score	Ligand rmsd (Å)	LGscore	MaxSub:
Receptor (spike)	6MOJ	B	196	1.000	100.0	-341.21	1.00	4.504	0.201
Ligand (ACE2)	7DMU	A	597	1.000	100.0			6.618	0.396

receptor's cytosolic third component are all shown in Figure 1. Figures 2-4 show the different views of STRA6 receptor, which bind to spike protein both extracellularly and at the membrane.

A virus's Receptor-Binding Domain (RBD), which is part of its "spike" region and allows docking to host receptors for entrance into cells and invasion, is an integral part, as shown in Figure 1. Here, we defined the Receptor-Binding Domain (RBD) of the SARS-CoV-2 S protein as observed that the RBD protein was tightly coupled to human STRA6 receptors. SARS-CoV-2 RBD attracted the STRA6 receptor considerably better than SARS-CoV RBD and was able to prevent activation. The RBD is a core part of viral spike glycoprotein or a crucial factor that allows virus infections to bind to various bodily receptors like the STRA6 receptors and readily penetrate to transmit illness is the attachment of the RBD to the spike domains.

Substantial research has focused on SARS-CoV-2 spike protein changes in the RBD throughout this aspect. A minimal investigation has been carried out on deletions and mutations in the N-Terminal Domain (NTD), which lies close to the RBD. Many of these are found inside certain sheet-linking loops that are particularly long in SARS-CoV-2 compared to SARS-CoV or other related retroviruses. We show that both short- and long-contacts are required for the maintenance of the spike protein's NTD loops in Figure 1, which are both essential for being detected by various autoantibodies. Isolates demonstrating great infectiousness may have an impact on the data of NTD loops, similar to alterations in amino acids. In Figure 1, we can see the cytosol area and extracellular membrane, where SARS spike protein is mostly concentrated in the lysosome and localised in the ER or ERGIC area, as per earlier research on intracellular trafficking and localisation. The several new motifs found in the cytoplasm of the SARS spike protein may aid in the localization of the ER or ERGIC.

Protein-Protein Interaction Network

The protein-protein interaction associative network for the STRA6 receptor through STRING server shows that the active interaction sources were set based on seven parameters: experiments, co-expression, gene fusion, co-occurrence, databases, text mining, and neighbourhood with a maximum of five interacting partners from both shells of interactions. The red colour node describes query proteins, and the other coloured nodes represent the first shell of interactors. The network interaction showed Interactions between STAR6 and other proteins have been observed. These proteins include RBP4 (Retinol-binding protein 4), which mediates retinol transport in blood plasma; TTR (Transthyretin), which transports thyroxine from the bloodstream to the brain; RBP1 (Retinol-binding protein 1), which accepts retinol from the transport protein as shown in Figure 4.

Binding energy analysis of STRA-6 and SARS CoV-2 spike protein complex

The interactive residues of the target protein STRA6 and the ligand spike protein may help design and develop potential anti-SARS CoV-2 drugs that are more efficacious and specific




Figure 1: In this diagram; we depict three parts of the STRA6 receptor protein, where we indicate RBD, NTD, extracellular, in tramembrane, and cytosol.




Figure 2: The SARS-CoV-2 pattern interactions of spike protein are captured via the TRA6 receptor based on docking. The three alternate forms of the SARS-CoV-2 spike protein are discernible with the TRA6 receptor, which seems before and after the viral and cell envelopes unite. We observed that spikes bind to human cells via the TRA6 Receptor and then undergo a dramatic conformational shift in the context of the SARS CoV-2 Spike Proteins in silico interactions. In the context of the TRA6 receptor, Spike Proteins link their outer membranes to the protection of human cells by folding in on themselves like a jackknife and further it opens the door to investigate coronavirus infection.

Table 2: STRA6 - SARS CoV-2 spike protein complex interaction data.

Receptor-ligand interface residue pair(s): STRA6 –SARS CoV-2 spike protein									
Amino acid residue	RMSD	Amino acid residue	RMSD	Amino acid residue	RMSD	Amino acid residue	RMSD	Amino acid residue	RMSD
98A - 446	4.825	401A - 500	3.923	531A - 455	4.937	408A - 498	4.101	540A - 494	4.607
101A - 445	2.600	401A - 501	4.401	531A - 456	3.806	409A - 449	3.185	543A - 403	3.484
101A - 446	3.688	404A - 446	3.954	531A - 489	1.928	412A - 449	4.520	543A - 505	2.466
121A - 345	3.385	404A - 498	2.828	532A - 486	3.480	511A - 478	2.965	544A - 505	4.859
122A - 440	3.806	404A - 500	4.395	532A - 487	3.408	511A - 486	3.152	701A - 483	4.559
122A - 441	3.261	404A - 501	4.772	532A - 489	2.782	512A - 480	4.585	701A - 484	2.855
125A - 440	1.963	405A - 449	4.362	535A - 489	3.116	512A - 481	4.318	519A - 484	4.235
125A - 441	3.276	405A - 496	3.025	538A - 417	2.815	512A - 483	3.595	530A - 489	4.709
128A - 443	3.229	405A - 498	2.076	538A - 453	4.823	512A - 484	4.812	531A - 455	4.937
128A - 444	3.081	405A - 501	3.038	538A - 455	3.064	515A - 484	3.589	531A - 456	3.806
128A - 445	3.690	405A - 505	4.742	538A - 456	3.345	515A - 485	3.286	531A - 489	1.928
128A - 499	4.986	407A - 446	4.932	538A - 493	4.770	515A - 486	3.288	532A - 486	3.480
129A - 499	4.782	408A - 446	2.397	539A - 455	4.610	516A - 484	4.592	532A - 487	3.408
393A - 405	2.898	408A - 447	4.521	540A - 453	4.496	519A - 484	4.235	532A - 489	2.782
393A - 408	3.542	408A - 449	2.841	540A - 493	3.539	530A - 489	4.709	535A - 489	3.116
393A - 504	4.869	408A - 498	4.101	540A - 494	4.607	531A - 455	4.937	538A - 417	2.815
394A - 403	4.451	409A - 449	3.185	543A - 403	3.484	531A - 456	3.806	538A - 453	4.823
394A - 405	4.088	412A - 449	4.520	543A - 505	2.466	531A - 489	1.928	538A - 455	3.064
394A - 505	2.945	511A - 478	2.965	544A - 505	4.859	532A - 486	3.480	538A - 456	3.345
395A - 505	4.958	511A - 486	3.152	701A - 483	4.559	532A - 487	3.408	538A - 493	4.770
397A - 501	4.170	512A - 480	4.585	701A - 484	2.855	532A - 489	2.782	539A - 455	4.610
397A - 502	3.186	512A - 481	4.318	405A - 449	4.362	535A - 489	3.116	540A - 453	4.496
397A - 503	4.476	512A - 483	3.595	405A - 496	3.025	538A - 417	2.815	540A - 493	3.539
397A - 504	4.045	512A - 484	4.812	405A - 498	2.076	538A - 453	4.823	540A - 494	4.607
397A - 505	2.104	515A - 484	3.589	405A - 501	3.038	538A - 455	3.064	543A - 403	3.484
398A - 505	2.971	515A - 485	3.286	405A - 505	4.742	538A - 456	3.345	543A - 505	2.466
400A - 500	3.268	515A - 486	3.288	407A - 446	4.932	538A - 493	4.770	544A - 505	4.859
400A - 501	3.411	516A - 484	4.592	408A - 446	2.397	539A - 455	4.610	701A - 483	4.559
400A - 502	3.860	519A - 484	4.235	408A - 447	4.521	540A - 453	4.496	701A - 484	2.855
401A - 498	4.759	530A - 489	4.709	408A - 449	2.841	540A - 493	3.539		

for their biological targets. The docking of STRA6 target protein with SARS CoV-2 spike protein reveals the involvement and interaction of the spike protein into the extracellular and membrane part of the STRA6 receptor and amino acids residues of STRA6. The corresponding distances for the residue contacts between proteins STRA6 and the spike protein are listed in Table 2.

Molecular Dynamics (MD) Simulation

In order to confirm the stability of the predicted docked ligand-ACE 2 and STRA 6 complexes, a study of all-atom

Molecular Dynamics (MD) simulations was carried out. Such a study would be helpful to get further understanding of the dynamic interactions between the ligand and the protein receptors 7DMU and 5SY1, as well as to assess the ligand's major binding contacts with important enzymatic domain regions. Therefore, a 100 ns all-atom MD simulation took into consideration the expected ligand-protein interactions for both the ACE 2 and STRA 6 proteins. We looked at the dynamic behavior of the ACE 2 (7DMU) and STRA 6 (5SY1) receptor proteins in complex with SARS CoV-2 spike protein as a complex as a consequence of the docking study results mentioned above. Calculations were




Figure 3: In this figure, we indicate the critical relation of the STRA6 receptor which is tightly complexed with spike protein and shows binding in the RBD as an extracellular domain. The docking serves as an essential step in SARS-CoV-2 infection in the context of RBD of the spike protein to the STRA6 receptor located on the surface of infected cells. Therefore, modifying it can have a big influence on health implications.




Figure 4: Protein-protein interaction network of STRA6 receptor.




Figure 5: Analysis of RMSF of the carbon alpha for 5A (ACE2-SARS CoV-2 spike protein complex) and 5B (STRA6-SARS CoV-2 spike protein complex).

made for the Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF). The primary goal of the MD simulation studies was to investigate the protein's positional and structural changes. Root Mean Square Fluctuation is a useful method for detecting regional changes throughout the chain of interactions involving a protein.

MD studies revealed the RMSF plot in Figure 5(A) and 5(B) for ACE 2-SARS CoV-2 spike protein complex and STRA6-SARS CoV-2 spike protein complex, respectively. An MD modeling investigation showed that simply changing the conformation of the N-terminal site in the range of 580:800, ACE 2 may successfully activate the biological pathway. The RMSF of the ACE 2 receptor protein in association with SARS CoV-2 spike protein was assessed, and the results showed that the protein has a high RMSF in the bound state that ranges from 0.6 to 5.6. The variations in RMSF suggest that the protein's structure has changed as a result of the binding of its residues to the ligand. The involvement of these residues in the interaction with the ligand is shown by a large variation in RMSF at the N-terminal locations.

The residue position 690 had the most variation. The outcomes, therefore, demonstrate an active interaction between the ligand and the target leading to protein conformational changes. STRA6 activates at the C-terminal in the range of 250-500 and then in the middle in the range of 500-1000 with significant RMSF ranging from 1.3-10.5. The residue position 270 had the most variation.

During the MD simulations, RMSD was utilized to assess the stabilities of the ACE 2 and STRA6 complex with the SARS CoV-2 spike protein for 100 ns for each trajectory frame. The protein complexes' time (ns) for frame x was calculated with respect to the original structures along the 100 ns trajectory using the provided trajectories. RMSD for ACE 2 was found to be 3.4 and 10.6 for STRA6 (Figure 6).

SSE structures such as α -helices β -strands were monitored throughout the simulation. Figure 7A and 7B report the SSE distribution by residue index throughout the protein structure. Figures 7C and 7D summarize the SSE composition for each trajectory frame over the course of the simulation. Figure 7E and 7F show each residue and its SSE assignment over time.




Figure 6: RMSD analysis of the 7A (ACE2– SARS CoV-2 spike protein complex) and 7B (STRA6 – SARS CoV-2 spike protein complex).

The SSE composition for each trajectory frame over the




Figure 7: SSE distribution by residue index throughout the protein structure 7A (ACE2–SARS CoV-2 spike protein), 7B (STRA6 – SARS CoV-2 spike protein). SSE composition for each trajectory frame over the course of the simulation (i.e., 100 ns) for 7C (ACE2– SARS CoV-2 spike protein), 7D (STRA6 – SARS CoV-2 spike protein). Monitoring of each residue and its SSE assignment over time for E (ACE2– SARS CoV-2 spike protein), F (STRA6 – SARS CoV-2 spike protein) (red and blue colors indicate SSE assignment, alpha helix and beta-strand, respectively).

simulation (i.e., 100 ns) was determined and shown in Figure 7. For the ACE2 complex, the α -helix and β -strand accounted for 46.98% of the total SSE, whereas the STRA6 complex was 45.38% of the total SSE.

CONCLUSION

Our aim is very diverse to explore the mechanistic process for the investigation of Retinol Receptor-STRA6 as a Novel Binding Receptor in SARS CoV-2 using some computational approaches where we strategize to anticipate the receptor usage infectivity of potential SARS-CoV to recognize their expected historical roots or genetic elements based on the patterns of their spike proteins and the known particle structural features of the initial SARS-CoV RBD/ACE2 complexes. Here, based on the newly published data of the 2019-nCoV RBD, we consistently use this forecasting methodology to provide unprecedented insights into the receptor use and anticipated capacity to invade 2019-nCoV. Here, using the SARS-CoV spike as a baseline, we investigate the receptor binding and protease activations of the SARS-CoV-2 spike. Our findings, which are based on computational analysis,

reveal important SARS-CoV-2 cell ingress pathways, where spike protein from the virus specifically binds to an integral receptor complex, probably assisting in signal transduction, cell transmissibility, and broad transmission (STRA6). We extensively examine the method by which STRA6, which recognizes RBP-retinol and triggers its release and internalization, facilitates Retinol (Vitamin A) absorption into cells. The findings settle prior claims on SARS-CoV-2, where Retinol and retinoic acid are promising options for COVID-19 infection and its unknown etiological symptoms. Our Mechanistic Investigations are very surprising strategies where Novel Binding Receptor in SARS CoV-2 provides breakthrough feedback to regulate RBD/ACE2 complexes in the context of Spike proteins to boost escaping immune regulation, that's why the current investigation provides a novel insight into prospective treatment means via targeting SARS-CoV-2 specific sites.

ACKNOWLEDGEMENT

The authors extend their appreciation to the Researchers Supporting Project number (RSPD2023R745), King Saud University, Riyadh, Saudi Arabia.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTIONS

Mahmoud Elkazzaz, Israa M. Shamkh and Amr Ahmed: Conceptualization Mahmoud Elkazzaz, Israa M. Shamkh, Amr Ahmed, Abdullah Haikal, data curation, formal analysis, investigation, methodology, software, validation, visualization, writing – original draft, writing – review, editing, validation, visualization, writing – original draft, writing – review and editing.

ABBREVIATIONS

STRA6: Signaling Receptor and Transporter of Retinol; **ACE2:** Angiotensin-converting enzyme 2.

REFERENCES

- Chen Y, Clarke OB, Kim J, Stowe S, Kim YK, Assur Z, et al. Structure of the STRA6 receptor for retinol uptake. *Science* (New York, N.Y.). 2016;353(6302):aad8266. <https://doi.org/10.1126/science.aad8266>.
- Kelly, Mary, Johannes von Lintig. "STRA6: role in cellular retinol uptake and efflux." *Hepatobiliary surgery and nutrition*. 2015;4(4):229-42. doi:10.3978/j.issn.2304-3881.2015.01.12
- Barrett, Crisha, et al. "Human Peripheral Blood Mononuclear Cells Express High Levels of the Vitamin A Transport Protein, Stimulated by Retinoic Acid 6 (P19-004-19)." *Current Developments in Nutrition*. 2019;3(1):P19-004-19. doi:10.1093/cdn/nzz049. P19-004-19
- Bouillet P, Sapin V, Chazaud C, Messaddeq N, Décimo D, Dollé P, Chambon P. Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein. *Mechanisms of Development*. 1997;63(2):173-86.
- Kawaguchi R, Yu J, Ter-Stepanian M, Zhong M, Cheng G, Yuan Q, et al. Receptor-mediated cellular uptake mechanism that couples to intracellular storage. *Sun HACS chemical biology*. 2011;6(10):1041-51.
- Isken A, Golczak M, Oberhauser V, Hunzelmann S, Driever W, Imanishi Y, et al. RBP4 disrupts vitamin A uptake homeostasis in a STRA6-deficient animal model for Matthew-Wood syndrome. *Cell Metabolism*. 2008;7(3):258-68.

7. Nair AK, Sugunan D, Kumar H, Anilkumar G. Case-control analysis of SNPs in GLUT4, RBP4 and STRA6: association of SNPs in STRA6 with type 2 diabetes in a South Indian population. *PLoS One*. 2010; 5(7):e11444.
8. Pasutto F, Sticht H, Hammersen G, Gillessen-Kaesbach G, Fitzpatrick DR, Nürnberg G, *et al.* Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation. *American Journal of Human Genetics*. 2007;80(3):550-60. <https://doi.org/10.1086/512203>
9. Ng WY, Pasutto F, Bardakjian TM, Wilson MJ, Watson G, Schneider A, *et al.* A puzzle over several decades: eye anomalies with FRAS1 and STRA6 mutations in the same family. *Clinical Genetics*. 2013;83(2):162-8.
10. Chassaing N, Golzio C, Odent S, Lequeux L, Vigouroux A, Martinovic-Bouriel J, *et al.* Phenotypic spectrum of STRA6 mutations: from Matthew-Wood syndrome to non-lethal anophthalmia. *Human Mutation*. 2009;30(5):E673-81
11. Ruiz A, Mark M, Jacobs H, Klopfenstein M, Hu J, Lloyd M, *et al.* Retinoid content, visual responses, and ocular morphology are compromised in the retinas of mice lacking the retinol-binding protein receptor, STRA6. *Investigative Ophthalmology and Visual Science*. 2012;53(6):3027-39.
12. Berry DC, Jin H, Majumdar A, Noy N. Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. *Proceedings of the National Academy of Sciences USA*. 2011;108(11):4340-5.
13. Palczewski K. Chemistry and biology of vision. *Journal of Biological Chemistry*. 2012;287:1612-9. doi: 10.1074/jbc.R111.301150.
14. Al Tanoury Z, Piskunov A, Rochette-Egly C. Vitamin A and retinoid signaling: Genomic and nongenomic effects. *Journal of Lipid Research*. 2013;54:1761-75. doi: 10.1194/jlr.R030833.
15. Goodman DS. Vitamin A and retinoids in health and disease. *The New England Journal of Medicine*. 1984;310:1023-31. doi: 10.1056/NEJM198404193101605.
16. Shirakami Y, Lee SA, Clugston RD, Blaner WS. Hepatic metabolism of retinoids and disease associations. *Biochimica et Biophysica Acta*. 2012;1821:124-36. doi: 10.1016/j.bbali.2011.06.023.
17. Di Masi A, *et al.* Retinoic acid receptors: From molecular mechanisms to cancer therapy. *Molecular Aspects of Medicine*. 2015;41:1-115. doi: 10.1016/j.mam.2014.12.003.
18. West KP, Jr. Extent of vitamin A deficiency among preschool children and women of reproductive age. *Journal of Nutrition*. 2002;132:2857S-66S.
19. Kin Ting Kam R, Deng Y, Chen Y, *et al.* Retinoic acid synthesis and functions in early embryonic development. *Cell and Bioscience*. 2012;2:11 <https://doi.org/10.1186/2045-3701-2-11>
20. Pino-Lagos K, Benson MJ, Noelle RJ. Retinoic acid in the immune system. *Annals of the New York Academy of Sciences*. 2008;1143:170-87. doi: 10.1196/annals.1443.017. PMID: 19076350; PMCID: PMC3826166.
21. Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by retinoic acid. *Journal of Immunology*. 2014;192(7):2953-8. PubMed PMID: 24659788. eng.
22. Ross AC, Stephensen CB. Vitamin A and retinoids in antiviral responses. *The FASEB Journal*. 1996;10(9):979-85. PubMed PMID: 8801180. Eng
23. Kim CH. Control of Innate and Adaptive Lymphocytes by the RAR-Retinoic Acid Axis. *Immune Network*. 2018;18(1):e1. doi: 10.4110/in.2018.18.e1. PMID: 29503736; PMCID: PMC5833116.
24. Daniel BC, *et al.* "Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses." *Proceedings of the National Academy of Sciences of the United States of America* vol. 2011;(108)11:4340-5. doi:10.1073/pnas.1011115108
25. Babon JJ, Varghese LN, Nicola NA. Inhibition of IL-6 family cytokines by SOCS3. *Seminars in immunology*. 2014;26(1):13-9. <https://doi.org/10.1016/j.smim.2013.12.004>
26. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, *et al.* SOCS3 negatively regulates IL-6 signaling *in vivo*. *Nature Immunology*. 2003;4(6):540-5. doi: 10.1038/ni931. Epub 2003 May 18. PMID: 12754505.
27. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY. An interferon-gamma-related cytokine storm in SARS patients. *Journal of Medical Virology*. 2005;75(2):185-94. doi: 10.1002/jmv.20255. PMID: 15602737; PMCID: PMC7166886.
28. Johnson HM, Lewin AS, Ahmed CM. SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19. *Frontiers in Immunology*. 2020;23(11):582102. doi: 10.3389/fimmu.2020.582102. PMID: 33193390; PMCID: PMC7644869.
29. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nature Reviews Immunology*. 2020;20:355-62. <https://doi.org/10.1038/s41577-020-0331-4>
30. Fedders R, Muenzner M, Schupp M. Retinol binding protein 4 and its membrane receptors: a metabolic perspective. *Hormone Molecular Biology and Clinical Investigation*. 2015;22(1):27-37.
31. Tepas PR, Vollenberg R, Fobker M, Kabar I, Schmidt H, Meier JA, *et al.* Vitamin A Plasma Levels in COVID-19 Patients: A Prospective Multicenter Study and Hypothesis. *Nutrients*. 2021;13:2173. <https://doi.org/10.3390/nu13072173>
32. Norseen J, Hosooka T, Hammarstedt A, Yore MM, Kant S, Aryal P, *et al.* Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. *Mol Cell Biol*. 2012;32(10):2010-9. doi: 10.1128/MCB.06193-11. Epub 2012 Mar 19. PMID: 22431523; PMCID: PMC3347417.
33. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine*. 2020;40(5):846-8. 10.1007/s00134-020-05991-x
34. Devaprasad A, Pandit A. Enrichment of SARS-CoV-2 entry factors and interacting intracellular genes in peripheral immune cells. *bioRxiv*; 2021. DOI: 10.1101/2021.03.29.437515
35. Zafar I, *et al.* Genome wide identification, phylogeny, and synteny analysis of sox gene family in common carp (*Cyprinus carpio*). *Biotechnology Reports*. 2021;30:e00607.
36. Ahmad SU, *et al.* A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries. *Journal of Infection and Public Health*, 2022;15(8): p. 878-891.
37. Elkazzaz M, Ahmed A, Abo-Amer YEE, Haydara T, Haikal A, Razek DNAE, *et al.* In Silico Discovery of GPCRs and GnRHRs as Novel Binding Receptors of SARS-CoV-2 Spike Protein Could Explain Neuroendocrine Disorders in COVID-19. *Vaccines*. 2022;10(9):1500.
38. Rather MA, Dhandare BC. Genome-Wide identification of doublesex and Mab-3-Related transcription factor (DMRT) genes in Nile tilapia (*Oreochromis niloticus*). *Biotechnology reports*, 2019;24:e00398.
39. Zafar I, *et al.* Genome-Wide Identification and Expression Analysis of PPOs and POX Gene Families in the Selected Plant Species. *Biosciences Biotechnology Research Asia*, 2020;17(2):301-18.
40. Karplus M, Petsko GA. Molecular dynamics simulations in biology. *Nature*, 1990; 347(6294):631-9.
41. Hornak V, *et al.* HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. *Proceedings of the National Academy of Sciences*, 2006;103(4):915-20.
42. Henzler-Wildman K, Kern D. Dynamic personalities of proteins. *Nature*, 2007;450(7172):964-72.
43. Lindahl ER. Molecular dynamics simulations, in *Molecular modeling of proteins*. 2008; Springer 3-23.
44. Dias R, Azevedo J, Walter F. Molecular docking algorithms. *Current drug targets*, 2008;9(12):1040-1047.
45. Agarwal S, Mehrotra R. An overview of molecular docking. *JSM Chemistry*, 2016; 4(2):1024-8.
46. Kitakaze T, *et al.* Extracellular transglutaminase 2 induces myotube hypertrophy through G protein-coupled receptor 56. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*. 2020;1867(2):118563.
47. Elkazzaz MR, *et al.* Discovery of the Retinol STRA6 Receptor as a Novel Binding Receptor for SARS-CoV-2 in COVID-19: In Silico Research, 2021.
48. Elkazzaz M, *et al.* STRA6 (vitamin A receptor), as a Novel binding receptor of COVID-19. *Research square Preprints*. 2021.
49. Shamkh IM, Al-Majidi M, Shntaif AH, Deng Kai PT, Nh-Pham N, Rahman I, *et al.* Nontoxic and Naturally Occurring Active Compounds as Potential Inhibitors of Biological Targets in *Liriomyza trifolii*. *International Journal of Molecular Sciences*. 2022;23(21): 12791.

Cite this article: Elkazzaz M, Ahmed A, Abo-Amer YE, Haydara T, ElTayb WA, Khan MS, *et al.* In silico Discovery of STRA 6 Vitamin A Receptor, as a Novel Binding Receptor of COVID-19. *Indian J of Pharmaceutical Education and Research*. 2023;57(4):1044-52.